NCT06866795View on ClinicalTrials.gov

Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
DRUG

GT-220F capsule

GT-220F capsule for oral administration

Sponsors
All Listed Sponsors
lead

Geode Therapeutics Inc.

INDUSTRY

NCT06866795 - Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Biotech Hunter | Biotech Hunter